

**Arbutus Biopharma Corporation  
701 Veterans Circle  
Warminster, Pennsylvania 18974**

January 8, 2020

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Re: Arbutus Biopharma Corporation  
Registration Statement on Form S-3  
Filed December 23, 2019  
File No. 333-235674  
Request for Acceleration of Effective Date

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Arbutus Biopharma Corporation hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the "Registration Statement") to become effective on January 10, 2020, at 4:00 p.m. Eastern Standard Time, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Steve Abrams of Hogan Lovells US LLP at (267) 675-4671.

**ARBUTUS BIOPHARMA CORPORATION**

By: /s/ David C. Hastings  
Name: David C. Hastings  
Title: Chief Financial Officer